Abemaciclib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ABEMACICLIB |
|---|---|
| Type | Drug |
| Aliases | VerzenioАбемацикліб |
| Status | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Drug Facts
| Class | CDK4/6 inhibitor (continuous dosing) |
|---|---|
| Mechanism | More CDK4-selective than CDK6 — different cycle dosing (continuous, not 21+7) and AE profile (more diarrhea, less neutropenia). Established adjuvant role (monarchE) for high-risk HR+/HER2- early breast. |
| Typical dosing | Metastatic: 150 mg PO BID continuous + AI/fulvestrant. Monotherapy: 200 mg PO BID. Adjuvant: 150 mg PO BID + ET for 2 years. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Adjuvant indication unique: monarchE established 2-year benefit for N+ HR+/HER2- ≥grade 3 OR ≥4 nodes. Continuous schedule + diarrhea-management distinguishes from palbociclib/ribociclib.
Used By
Regimens
REG-ABEMACICLIB-ADJUVANT- Abemaciclib adjuvant (HR+/HER2- early high-risk breast cancer)REG-FULVESTRANT-ABEMACICLIB- Fulvestrant + abemaciclib (HR+/HER2- metastatic 2L post-AI)